Drug resistance mutations to integrase inhibitors, proteinase, and reverse transcriptase inhibitors in newly diagnosed HIV-1 infections in Hebei province, China, 2018-2022. [PDF]
Lu X+6 more
europepmc +1 more source
Addressing Cardiometabolic Challenges in HIV: Insights, Impact, and Best Practices for Optimal Management-A Narrative Review. [PDF]
Mugisha N+7 more
europepmc +1 more source
Higher Genotyping Performance of the Applied Biosystems TaqPath Seq HIV-1 Genotyping Kit Against ViroSeq HIV-1 Genotyping Kit in HIV <i>Protease</i>, <i>Reverse Transcriptase</i>, and <i>Integrase</i> Regions. [PDF]
Choga OT+7 more
europepmc +1 more source
Exploring Zinc C295 as a Dual HIV-1 Integrase Inhibitor: From Strand Transfer to 3'-Processing Suppression. [PDF]
Sayyed SK+8 more
europepmc +1 more source
Change in Blood Pressure, Weight, and Other Cardiovascular Disease Risk Factors After Switch From Protease Inhibitors to Dolutegravir: Post hoc Analysis of the 48-week Randomised Second-line Switch to Dolutegravir Trial. [PDF]
Ombajo LA+7 more
europepmc +1 more source
Emergence of Bictegravir Resistance in a Treatment-Experienced PWH on Functional Monotherapy and Rapid Replacement by an Ancient Wild-Type Strain Following Transient Treatment Interruption. [PDF]
Faré PB+7 more
europepmc +1 more source